![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Medicure Reports Positive Preclinical Results for Novel Antithrombotic
Medicure Reports Positive Preclinical Results for Novel Antithrombotic
Medicure has announced positive results from the preclinical studies of the company's discovery drug candidate, MC-45308.
The studies examined the anticoagulant and antiplatelet activities of MC-45308 in both in vitro and in vivo experiments. The anticoagulant effects of MC-45308 were evaluated with a series of recognized lab tests used to monitor the clotting ability of whole blood. The global anticoagulant assay, which measures activated clotting time, was used to compare MC-45308 to the clinically approved anticoagulants bivalirudin and argatroban (direct thrombin inhibitors) at concentrations of 5 mcg/mL. In this test, MC-45308 compared favorably to both bivalirudin and argatroban by prolonging the activated clotting time further when used at the same concentration.
A second set of experiments involved the rabbit venous stasis model of thrombosis, which is commonly used to screen therapeutic compounds for antithrombotic activities. In this model, MC-45308 was more effective than both bivalirudin and argatroban when administered intravenously at a dose of 250 mcg/kg, effecting an approximately 80 percent reduction in clot score. The comparative bleeding profile of MC-45308, bivalirudin and argatroban were similar in this model, suggesting that MC-45308 may share a similar safety profile.
When tested against a variety of clinically relevant agonists including ADP, collagen and ristocetin, MC-45308 inhibited aggregation induced by each of these agonists, with the most pronounced effect seen in ADP induced aggregation. Inhibition of ADP-induced platelet aggregation has proven to be an effective clinical strategy in the management of a number of cardiovascular indications, including acute coronary syndromes, peripheral arterial disease, myocardial infarction and stroke, as evidenced by the success of the antiplatelet drug clopidogrel.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct